TEVETEN TABLETS 300 MG

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

EPROSARTAN (EPROSARTAN MESYLATE)

Διαθέσιμο από:

SOLVAY PHARMA INC

Φαρμακολογική κατηγορία (ATC):

C09CA02

INN (Διεθνής Όνομα):

EPROSARTAN

Δοσολογία:

300MG

Φαρμακοτεχνική μορφή:

TABLET

Σύνθεση:

EPROSARTAN (EPROSARTAN MESYLATE) 300MG

Οδός χορήγησης:

ORAL

Μονάδες σε πακέτο:

60

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0137701001; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

1999-08-19

Αρχείο Π.Χ.Π.

_ _
_Appendix E - Product Monograph Template – Standard (DRAFT) –
March 29, 2005 _
_Page 1 of 35_
PRODUCT MONOGRAPH
Pr
TEVETEN
®
Eprosartan Mesylate Tablets
(containing 400 mg and 600 mg eprosartan)
Angiotensin II receptor (AT
1
) antagonist
Date of Preparation:
August 20, 1999
Date of Revision:
May 25, 2006
Submission Control No: 099001
_ _
_Appendix E - Product Monograph Template – Standard (DRAFT) –
March 29, 2005 _
_Page 2 of 35_
Table of Contents
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................6
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND
ADMINISTRATION..............................................................................12
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND
STABILITY..........................................................................................17
SPECIAL HANDLING INSTRUCTIONS
.......................................................................17
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................17
PART II: SCIENTIFIC INFORMATION
...............................................................................19
PHARMACEUTICAL
INFORMATION....................................